Table 3.
Experimental Group | Age | Diabetes (duration) | Synapses (#) | Presynaptic Axon Terminal Cross Sectional Area (square microns) |
---|---|---|---|---|
NOD Mice | ||||
SMG-CGs | ||||
Control (n = 6) | 6 months | 74 ± 12 | 0.75 ± 0.06 | |
Diabetics (n = 5) | 6 months | 3–5 weeks | 92 ± 4 | 1.33 ± 0.14* |
SCG | ||||
Controls (n = 3) | 6 months | 60 ± 6 | 0.97 ± 0.02 | |
Diabetics (n = 3) | 6 months | 3–5 weeks | 48 ± 10 | 0.82 ± 0.03# |
B6D2F1 + STZ Exp | ||||
Controls (n = 3) | 6.5 months | 111 ± 18 | 0.75 ± 0.05 | |
Diabetics (n = 4) | 6.5 months | 5 months | 97 ± 12 | 1.28 ± 0.08* |
C57BL6 + STZ | ||||
Controls (n = 3) | 4–6 months | 83 ± 16 | 0.76 ± 0.04 | |
Diabetics (n = 5) | 4–6 months | 3–4 months | 59 ± 3 | 1.15 ± 0.06* |
NOD-SCID + STZ | ||||
Controls (n=4) | 3 mo | 75 ± 10 | 0.91 ± .04 | |
Diabetics (n=5) | 3 mo | 2–4 weeks | 88 ± 7 | 1.28 ± 0.04* |
Values represent the means ± SEM of the mean cross-sectional area of 50 to 125 synapses sampled from each of n mice. Statistical comparison:
p ≤ 0.01;
p ≤ 0.05.